Mr. David J. Main
President & CEO
Mr. Main has over 25 years experience in the pharmaceutical industry and brings a demonstrated ability to grow and finance pharmaceutical development companies. As a co-founder of Aquinox, Mr. Main has overseen the advancement of the Company’s lead product, AQX-1125, from a target validation program to now entering Phase 3 studies. During this time he has also been responsible for the transition of Aquinox from a private to a NASDAQ-listed public company with over US$200 million raised to date in equity capital. Mr. Main was formerly the President and CEO of INEX Pharmaceuticals Corp. and, prior to INEX, was Vice President at QLT Inc., one of Canada’s inaugural biotech companies. Mr. Main began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He holds a B.Sc. (Pharmacy) and an MBA from the University of British Columbia (UBC). Mr. Main formerly served as the Chair of LifeSciences BC (formerly BC Biotech), is currently the Chair of BIOTECanada and a Director of BIO.org as well he also serves on a number of private and not-for-profit Boards.
Mr. Kamran Alam
VP, Finance & Chief Financial Officer
Mr. Alam has over 15 years' experience in the pharmaceutical industry and brings a demonstrated ability to finance and identify strategic opportunities for biotechnology companies. Mr. Alam was most recently the Senior Director, Business Development of Sirius Genomics where he worked directly with the CEO playing a lead role in planning and executing the company's business and financial strategy. Previously he has held senior business roles at the Centre for Drug Research and Development (CDRD), Angiotech Pharmaceuticals and AnorMED. Mr. Alam started his career as a Chartered Accountant with PriceWaterhouseCoopers (PWC) as a member of their Life Sciences Practice and gained valuable experience in the financing, auditing and tax structuring of a number of biotechnology and technology companies. Mr. Alam's diverse industry experience has provided him with an opportunity to participate in numerous and varied finance transactions, partnering deals and mergers and acquisitions in the U.S.A., Canada, Europe, and Asia. In addition to his CA designation, Mr. Alam possesses an MBA in International Business and Strategy from the University of Victoria as well as a B.Sc. in Cell Biology and Genetics from the University of British Columbia.
Mr. Paul Brennan
VP Business Development
Mr. Brennan brings more than 25 years of experience in building and leading pharmaceutical and biotechnology companies in the United States, Europe and Canada with a strong track-record in partnering and licensing transactions. Previously, Mr. Brennan was Senior Vice-President of Business Development at Arbutus Biopharma Corp. (formerly Tekmira Pharmaceuticals Corp.) prior to which he served as CEO of Altair Therapeutics, Inc. In past roles Mr. Brennan contributed to the sale of Aspreva Pharmaceuticals Corp. to Vifor Pharma Ltd. for $915 million and the sale of AnorMED Inc. to Genzyme Corp. for $580 million. Mr. Brennan also served in senior business development and regulatory affairs roles with AstraZeneca PLC, operating in Sweden, the United Kingdom and Canada.
Dr. David Green
VP, Global Clinical Operations
Dr. Green has over 21 years of clinical trial operations experience in academic, bio-pharmaceutical, and CRO settings. Most recently, Dr. Green was Executive Director at United Therapeutics leading global clinical operations for developmental drug candidates targeting orphan disease indications. Prior to that he was the Vice President of Global Clinical Operations & Biometrics at ReSearch Pharmaceutical Services, Executive Director of Clinical Operations at Amgen, and Clinical Program Manager at Abbott Labs. Dr. Green has a diverse set of global clinical operations experiences across multiple therapeutic areas. He brings a depth of experience in the development, implementation, execution, and management of clinical trial operations and clinical drug development in all Phases of clinical development.
Mrs. Abigail Jenkins
Chief Commercial Officer & US Business Head
Mrs. Jenkins has amassed nearly 20 years of commercial leadership experience spanning start-up Biotech enterprises to large Pharmaceutical companies. She specializes in launching brands into markets with high unmet clinical needs and brings expertise leading strategic marketing, sales, and market access functions. Most recently Mrs. Jenkins served as Vice- President, Market Access at Relypsa, Inc. where she played a key role in building commercial infrastructure to support the successful launch of its lead CV/Nephrology product in 2015. Mrs. Jenkins previously served as Vice President, Business Development at Actavis, Inc. (now Allergan PLC) as well as Senior Director of Marketing at MedImmune, Inc., where she led cross-functional teams to devise and implement marketing strategies that successfully drove increased revenue and profitability for a billion dollar monoclonal antibody franchise. Mrs. Jenkins also brings eight years of senior marketing and sales experience with Pfizer Inc.
Mr. Lloyd Mackenzie
VP, Technical Operations
Mr. Mackenzie joined Aquinox in May 2008 and was recently promoted to Vice President in May of 2013. Responsible for the company's Research and Development activities, Mr. Mackenzie has over 12 years of experience in the biopharmaceutical industry with expertise in medicinal chemistry, biochemistry and CMC. He is the author of 15 scientific publications and is an inventor on four patents. Prior to joining Aquinox, Mr. Mackenzie was a Research Scientist for Pharmaceutical Development at QLT Inc.. Prior to that, Mr. Mackenzie was a Research Scientist at Inflazyme Pharmaceuticals Inc.
Ms. Shelley McCloskey
VP, Human Resources & Administration
Ms. McCloskey has over 15 years of human resources leadership experience in the health industry. Most recently, Ms. McCloskey was Vice President, Human Resources at Stemcell Technologies Inc. (Stemcell), Canada's largest life sciences company by number of employees, with operations in North America, Europe and Asia Pacific. Prior to joining Stemcell in 2010, Ms. McCloskey was Vice President, Human Resources at Xantrex Technology Inc., a publically traded global advanced renewable energy and power electronics company acquired by Schneider Electric for C$500M in 2008. From 2000 to 2005, Ms. McCloskey served as Vice President, Human Resources and Information Systems at Inex Pharmaceuticals Inc. helping that Company grow from 40 to 225 employees.
Mr. David Mitchell
VP, Global Regulatory Affairs & Quality Assurance
Mr. Mitchell brings to Aquinox over 30 years regulatory experience including negotiations with the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), facilitating new drug and biologics development and approvals. Previously, Mr. Mitchell led global regulatory strategy in oncology, immunology, and neuroscience development at AbbVie, Inc. (North Chicago, IL), Biogen Idec (San Diego, CA), Bayer AG (Leverkusen, Germany), and The Upjohn Company (Kalamazoo, MI). Additionally, he was responsible for building the Regulatory and Quality infrastructure at several small biotechs in the United States. He presently serves on the Global Committee of The Food and Drug Law Institute (Washington, D.C.) where he provides advice on program and policy development in global food and drug law. Mr. Mitchell holds a M.Sc. degree in Bioscience Regulatory Affairs from The Johns Hopkins University (Baltimore, MD) and a BS in Chemistry degree from Mississippi College (Clinton, MS).
Dr. Barbara Troupin
Chief Medical Officer & VP, Clinical Development
Dr. Troupin joined Aquinox in September of 2016 with over more than 18 years Dr. Troupin has led clinical development and strategy at multiple, leading clinical research institutions and within the therapeutic drug development sector. Dr. Troupin most recently served as Senior Vice President and Chief Medical Officer at Apricus Bioscience, Inc. where she led the development and execution of clinical strategy for three drug development programs ranging from proof-of-concept to NDA filing, including Vitaros for the treatment of erectile dysfunction. Prior to Apricus, Dr. Troupin held the role of Vice President in Medical Affairs at VIVUS, Inc. where she led risk evaluation and mitigation strategy for Qsymia to treat weight loss, while also building relationships with thought leaders and key opinion leaders (KOLs). Dr. Troupin received her Doctorate in Medicine in 1995 from the University of Pennsylvania School of Medicine where she also completed her Master's in Business Administration, with an emphasis in health care management, from the Wharton School of Business.